Gene
FANCA
FANCA is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (13), Actionable biomarkers (2), Trial mentions (64), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention FANCA. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 4 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 3 of 8,738 | 0.03% | not measured | |
| 2025 | 3 of 8,875 | 0.03% | not measured | |
| 2024 | 3 of 8,597 | 0.03% | not measured | |
| 2023 | 5 of 8,275 | 0.06% | 9 of 11,460 | 0.08% |
| 2022 | 8 of 8,285 | 0.10% | 22 of 13,598 | 0.16% |
| 2021 | 8 of 8,692 | 0.09% | 19 of 15,045 | 0.13% |
| 2020 | 12 of 7,640 | 0.16% | 14 of 14,459 | 0.10% |
| 2019 | 9 of 7,300 | 0.12% | 8 of 12,159 | 0.07% |
| 2018 | 6 of 6,927 | 0.09% | 4 of 11,854 | 0.03% |
| 2017 | 3 of 6,558 | 0.05% | 3 of 11,595 | 0.03% |
Showing 10 of 37 years.
Assay-provider ledger (13)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| University of Minnesota Genomics Center | Not a company | Clinical validationAnalytical validation | 1 | April 01, 2026 |
| Agilent Technologies | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | April 08, 2021 |
| Anbiping Medical Laboratory | Diagnostic provider | No clinical or analytical validation recorded for this pair | 1 | April 08, 2021 |
| AB Applied Biosystems | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | April 08, 2021 |
| BIO-RAD | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | April 08, 2021 |
Showing 5 of 13 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| FANCA oncogenic mutation | OLAPARIB | response-associated | prostate adenocarcinoma | Cancer Genome Interpreter |
| FANCA deletion | OLAPARIB | response-associated | prostate adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (64)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04890613 | Trial eligibility (AACT) |
| NCT04171700 | Trial eligibility (AACT) |
| NCT03413995 | Trial eligibility (AACT) |
| NCT03533946 | Trial eligibility (AACT) |
| NCT05498272 | Trial eligibility (AACT) |
Showing 5 of 64 trial mentions.
Target-disease associations (871)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY complete gonadal dysgenesis | cardiovascular disease | Mouse knockout (IMPC) |
| 46,XY disorder of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency | endocrine system disease | Mouse knockout (IMPC) |
Showing 5 of 871 associations.
Vendor sourcing (268)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v2.1.1 dataset. Stop-gained (nonsense): predicted to result in a loss or disruption of normal protein function thro... | View ClinVar record SCV002521385.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The FANCA c.1874G>C; p.Cys625Ser variant (rs139235751, ClinVar Variation ID 265136) is reported in the literature in few individuals with Fanconi anemia, but... | View ClinVar record SCV000603559.2 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Patients must have a histologically documented (either primary or metastatic site) diagnosis of advanced solid tumor cancer (stage IV or unresectable) o... | View trial NCT03061188 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | FANCA | View trial NCT03061188 |
| Abramson Cancer Center | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma (mixed histology will be acceptable, but pure small cell histology is to... | View trial NCT04288687 |
Showing 5 of 268 sourcing records.
Trial-cited literature (114)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials. | Lancet (London, England) | 2025 | 21 |
| Prognostic significance of mutation type and chromosome fragility in Fanconi anemia. | American journal of hematology | 2025 | 12 |
| LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes. | JCO precision oncology | 2025 | 2 |
| First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. | Nature medicine | 2024 | 130 |
| Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023 | 305 |
Showing 5 of 114 papers.
Protein variant mentions (204)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A1066P | 1 | 2015 | PMID 25741868 |
| p.A10T | 1 | 2015 | PMID 25741868 |
| p.A1125T | 1 | 2015 | PMID 25741868 |
| p.A1141D | 2 | 2015 | PMID 25741868, PMID 26580448 |
| p.A1215D | 2 | 2015 to 2016 | PMID 27997549, PMID 25741868 |
Showing 5 of 204 variants.
Literature-extracted relations (19)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Platinum | Chemical | associate |
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. | 2015 |
| Neoplasms | Disease | associate |
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes. | 2025 |
| Anemia, Hemolytic | Disease | associate |
Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials. | 2025 |
| Bone Marrow Failure Disorders | Disease | associate |
Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials. | 2025 |
| Fanconi Anemia | Disease | associate |
Prognostic significance of mutation type and chromosome fragility in Fanconi anemia. | 2025 |
Showing 5 of 19 relation assertions.
Organizations publishing (275)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 12 | 2014 to 2022 |
| Dana-Farber Cancer Institute | Other | 10 | 2014 to 2025 |
| Government of the United States of America | Government | 8 | 2014 to 2023 |
| Université Paris-Saclay | Academic | 8 | 2021 to 2025 |
| CERCA Institution | Government | 6 | 2014 to 2025 |
Showing 5 of 275 organizations.
Where FANCA appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- psychiatric disorder
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
790 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.